Skip to main content
. 2020 Jun 30;52(4):1103–1111. doi: 10.4143/crt.2020.337

Table 1.

Clinicopathologic characteristics of the patients (resolution [width×height] of digital slide: 93,970×234,042)

Training set (n=157) Development set (n=40) Validation set (n=100) p-valuea)
Age (yr) 50 (28-80) 49 (30-68) 47 (34-75)
Sex
 Female 157 (100) 40 (100) 100 (100) > 0.99
Metastatic carcinoma
 Present, size > 2 mm 68 (43.3) 14 (35.0) 40 (40.0) 0.158
 Present, size ≤ 2 mm 35 (22.3) 5 (12.5) 15 (15.0)
 Absent 54 (34.4) 21 (52.5) 45 (45.0)
Neoadjuvant systemic therapy
 Not received 80 (51.0) 28 (70.0) 45 (45.0) 0.027
 Received 77 (49.0) 12 (30.0) 55 (55.0)
Histologic type
 IDC 149 (94.9) 32 (80.0) 86 (86.0) 0.005b)
 ILC 8 (5.1) 5 (12.5) 11 (11.0)
 MC 0 0 3 (3.0)
 Metaplastic carcinoma 0 3 (7.5) 0
Histologic grade
 1 or 2 118 (75.2) 34 (85.0) 86 (86.0) 0.074
 3 39 (24.8) 6 (15.0) 14 (14.0)

Values are presented as median (range) or number (%). IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; MC, mucinous carcinoma.

a)

p-values, calculated using the chi-square test,

b)

For the histologic type, a chi-square test was conducted between IDC and non-IDC.